Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

pfw2141 53 posts  |  Last Activity: May 4, 2015 9:45 AM Member since: Apr 9, 2005
  • Reply to

    Be back tomorrow !!!

    by pfw2141 May 4, 2015 9:30 AM
    pfw2141 pfw2141 May 4, 2015 9:45 AM Flag

    One more thought before going to the green, this may be,our last chance to buy KERX at this bargain price,
    jmho, Adios............................

  • Golf all day, no sense to cry or been miserable, close your PC , that the best remedy for this week, au revoir !!

  • pfw2141 by pfw2141 May 4, 2015 6:50 AM Flag

    Keryx Biopharmaceuticals Inc Earnings Call (Q1 2015)
    Scheduled to start Mon, May 4, 2015, 8:00 am Eastern

  • PREVIOUS JOB 01/02/2013
    chief commercial and commercial experience and extensive leadership skills
    GREAT, I HOPE HE STAY LONGER THAN 2 YEARS
    LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 2, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of Greg Madison as executive vice president and chief commercial officer. Mr. Madison brings a wealth of hands-on commercial experience and extensive leadership skills to AMAG. He joins AMAG from Genzyme Corporation, where he spent the past 12 years in various commercial roles in their renal division, most recently as the division’s vice president and general manager.
    “Through his distinguished career at Genzyme, Greg has had the opportunity to lead almost every commercial function relevant to buy-and-bill products, which makes him uniquely qualified to lead the commercial team at AMAG and drive the continued growth of Feraheme®,” said William Heiden, president and chief executive officer of AMAG. “His experience in the chronic kidney disease (CKD) market will help us identify new ways to drive growth of Feraheme within our current indication.”
    Heiden continued, “Additionally, Greg has driven the strategy development, planning and execution of several product launches – this experience will be invaluable to AMAG as we prepare for the potential regulatory approval of Feraheme for the treatment of iron deficiency anemia in a broader patient population. We will also benefit from Greg’s broad experience in our business development efforts, as he will play a key role in the evaluation and the commercialization of new acquired or in-licensed assets in the future. We are really pleased to welcome Greg to AMAG.”

    BOSTON, April 30, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), the "Company today announced the completion of the previously announced transition of the CEO role from Ron Bentsur to Greg Madison.

    Sentiment: Strong Buy

  • Effective as of April 30, 2015, Mr. Ron Bentsur stepped down as the Chief Executive Officer

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 30, 2015 2:08 PM Flag

    Yes, this is a winner with a big pipeline, very transparent with a nice future.
    They are in Marseille FRANCE

    Are you familiar with "Stag's Leap Wine Cellar Cab Cask 23" ?

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 30, 2015 1:22 PM Flag

    Thank you for this fact, they have more Doctor now compare with last year, who this is a plus, BRAVO
    Also some experts mention that KERX could go low as $9.00 and take off to $30.00
    this year, so patience, buy more now and don't sell, this manipulation is made to push people to sell.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 30, 2015 11:41 AM Flag

    Yes catalane , you are right,
    and it is not funny, this is sad
    Citadel Securities has quietly become one of the largest forces in U.S. stock trading.

    From the 35th floor of a downtown Chicago office tower, Citadel executes one out of every eight stock trades in the United States. At roughly 900 million shares a day, more stocks move through Citadel's systems than the New York Stock Exchange, which trades roughly 700 million shares a day.

    If you own a 401(k) or have ever used an online broker, your trades have almost certainly passed
    The computers that run the stock market -
    money.cnn.com/2013/07/08/investing/stock-market-citadel/
    CNNMoney
    - Welcome to the new world of trading: More and more, high speed computer programs are replacing thousands of floor brokers once seen ..

    Sentiment: Strong Buy

  • Reply to

    Dear Hillary: LIAR LIAR Pantsuit on Fire

    by morsecode830 Apr 30, 2015 11:06 AM
    pfw2141 pfw2141 Apr 30, 2015 11:21 AM Flag

    BUT....if you are a normal Conservative Rep Citizen, you go to jail with the blessing of the media and you cannot run for ANY Office position, NONE.

  • Reply to

    This is why ri66 is a short

    by poorpicks23 Apr 27, 2015 8:15 AM
    pfw2141 pfw2141 Apr 27, 2015 9:49 AM Flag

    This men is operating from a asylum or making license plates, with plenty time to post his garbage , yes you are right poorpick everyone should flag him + ignore and up "Au revoir" for good

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 23, 2015 10:13 AM Flag

    He may bring some others products to KERX pipeline, like He have done with the Renal Drugs Advisory Committee

    Sentiment: Strong Buy

  • Reply to

    Auryxia is now covered by Medicare.

    by tshn95 Apr 21, 2015 3:42 AM
    pfw2141 pfw2141 Apr 21, 2015 10:00 AM Flag

    Well call your Congressman/Woman to stop and declare shorting a stock unlawful , they have done it in Germany, it is possible.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 20, 2015 4:45 PM Flag

    In France we eat them in a Rutherford shifter Cognac glass , a la votre!

  • pfw2141 pfw2141 Apr 20, 2015 3:25 PM Flag

    I would know how to short, please read my post again, your statement is irrelevant and inappropriate of the subject, you are wasting your time and mine. Disparait , tu n'es pas bienvenue dans mon Monde. Merci.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 20, 2015 1:50 PM Flag

    Catalane
    My statement was very mild, more a question than a blame.
    "cautious because previous failure ?, No I don't think so, they have been approved. "
    Many of the best Chemist have come across some failure, this is life, the problem for these people are the shares holder and the Board of Dir of their Company.

  • pfw2141 pfw2141 Apr 20, 2015 12:50 PM Flag

    I don't make story, sorry, I lost some money , my fault I should have study with more caution and I NEVER make any statement if I am not sure of the source.
    From the W S J.
    Apr 2, 2012 ... After the inevitable stock fall, biotech investors can learn a lesson or two from Keryx Pharma's failure.. Keryx Biopharmaceuticals Inc(KERX)
    NEW YORK -- Observations and lessons from the blowups in Keryx Pharmaceuticals (KERX - Get Report) (down 65% to $1.75 per share) and Aeterna Zentaris (AEZS - Get Report) (down 65% to 74 cents per share) due to the failure of the colon cancer drug perifosine

  • pfw2141 pfw2141 Apr 20, 2015 11:48 AM Flag

    What don't Kerx management speak up? Maybe they cannot spray any news, cautious because previous failure, I don't think so they have been approved. Same scenario of last week
    Something is cooking, maybe finally the all picture will show up. Patience..........we will be rewarded.......

  • Reply to

    OLD NEWS TO REMIND EVERYBODY,THIS IS TEMPORARY!!!!!!!

    by pfw2141 Apr 17, 2015 10:05 AM
    pfw2141 pfw2141 Apr 17, 2015 10:09 AM Flag

    Close your Computer , and go fishing or golfing, anything but don't watch the market , we probably will close on the green.
    From Paris bon weekend et une bonne bouteille de Cab "Silver Oak Napa bien sur.

  • Conclusions
    You can relax investors. There is still a market for Keryx. That's because Keryx's drug is aimed to treat patients with end-stage renal disease. There are an estimated 600,000 ERSD patients in the U.S. currently and that number is expected to grow.
    Seth Klarman makes smart investments, and he is patient. The good thing is that since the market has corrected, Keryx is trading at a discount. Just because KERX has increased in value exponentially in the past few years, does not mean that it has lost its underlying value.

    Baupost raises position in Keryx Biopharmaceuticals
    Why Did Baupost Double Its Stake In Keryx Biopharmaceuticals?

    When Baupost makes a buy, investors pay attention.
    The fund recently doubled its stake in Keryx, and now owns 19.8% of the company.
    1 in 10 American adults have some level of chronic kidney disease (CKD).
    Current treatments for hyperphosphatemia in patients on dialysis are ineffective.
    Most recently, Keryx has secured a U.S. patent for ferric citrate as treatment of hyperphosphatemia.

    When Baupost makes a buy, investors pay attention. That's because Seth Klarman and his fund have hit numerous 'homeruns,' like Micron Technology (NASDAQ:MU) and Idenix Pharmaceuticals (NASDAQ:IDIX). So what does this hedge fund manager extraordinaire see in Keryx (NASDAQ:KERX)?
    Chronic Kidney Disease (CKD)

    Keryx Biopharmaceuticals is developing a drug to treat patients with chronic kidney disease. In 2009, overall Medicare expenditures for people with CKD totaled $33.8 billion. The most common causes of CKD are high blood pressure and diabetes.
    It is estimated that one in 10 American adults have some degree of CKD. That's roughly 20 million Americans. And that number keeps growing.
    The Baupost Group raised its position in Keryx Biopharmaceuticals (KERX) that accounted for 4.38% of the fund’s total third-quarter portfolio. The fund owns 18,300,000 shares, up from 10,539,986 shares in 2Q14.

    Sentiment: Strong Buy

  • pfw2141 pfw2141 Apr 14, 2015 4:27 PM Flag

    Il est fou ce type, il opere son coordinateur directement d'un asile ou d'une prison,
    Il ne faut pas lui repondre, cest probablement un ancien liberal socialist professor de phylosophy de Harvard

AEZS
0.528-0.022(-4.09%)May 5 4:00 PMEDT